Acute lymphoblastic leukemia (ALL) is a fast-growing cancer of the blood and bone marrow in which the body produces too many immature white blood cells, called lymphoblasts. These abnormal cells crowd out the healthy blood cells your body needs to fight infections, carry oxygen, and control bleeding. It is the most common childhood cancer, but it also occurs in adults, where it tends to be harder to treat. The five-year survival rate for children under 15 has reached roughly 90%, up from 60% in the 1970s.
How ALL Develops in the Body
Blood cells are made inside your bone marrow, the spongy tissue in the center of large bones. Normally, immature cells called stem cells develop into fully functioning red blood cells, white blood cells, and platelets in an orderly process. In ALL, something goes wrong at an early stage of that process. A single immature cell acquires genetic changes that cause it to multiply uncontrollably, resist the normal signals that would trigger cell death, and fail to mature into a working white blood cell.
Because these defective lymphoblasts keep dividing, they eventually take over the bone marrow. That leaves less and less room for the production of normal blood cells. The result is a shortage of red blood cells (anemia), a shortage of platelets (which help with clotting), and a shortage of the mature white blood cells that fight infection. The leukemia cells can also spill into the bloodstream and, in some cases, infiltrate the central nervous system or other organs.
Recognizing the Symptoms
The symptoms of ALL develop because the bone marrow can no longer make enough healthy blood cells. They often come on quickly, over days to weeks, and can include:
- Fatigue, weakness, and pale skin from low red blood cell counts
- Easy bruising, frequent nosebleeds, or bleeding gums from low platelet counts
- Frequent or severe infections and fevers from a lack of functional white blood cells
- Bone or joint pain, especially in children, caused by leukemia cells accumulating in the marrow
- Swollen lymph nodes in the neck, armpits, abdomen, or groin
- Shortness of breath
None of these symptoms is unique to leukemia, which is part of what makes early recognition tricky. A routine blood test that shows abnormal cell counts is often the first clue.
How ALL Is Diagnosed
Diagnosis starts with a complete blood count, which typically reveals a high number of immature white cells alongside low numbers of red blood cells and platelets. But a blood test alone is not enough. The definitive step is a bone marrow biopsy, in which a small sample of marrow is drawn from the hip bone with a needle.
That sample is examined in several ways. Under a microscope, pathologists look at the shape and number of blast cells. A technique called flow cytometry passes individual cells through a laser to identify specific proteins on their surface, which helps confirm the exact subtype of ALL (most cases arise from B cells, while a smaller share arise from T cells). Molecular testing looks for specific genetic changes in the leukemia cells. These genetic details matter enormously because they influence both prognosis and treatment decisions.
What Determines Risk Level
Not all ALL behaves the same way. Doctors classify each case into a risk group based on several factors: the patient’s age at diagnosis, initial white blood cell count, the genetic makeup of the leukemia cells, and how quickly the cancer responds to the first round of treatment.
Certain genetic changes carry a worse outlook. A chromosomal abnormality called the Philadelphia chromosome, found in about 3 to 5% of pediatric ALL cases and a larger share of adult cases, was historically one of the most concerning markers. The addition of targeted drugs that block the protein this chromosome produces has improved outcomes significantly. Other high-risk genetic features include complex chromosomal patterns, very low chromosome numbers in the leukemia cells, and rearrangements in specific genes. Patients whose cancer takes longer than four weeks to reach remission, or who still have detectable leukemia cells after initial treatment, are also placed in higher-risk categories.
Treatment Phases and Timeline
Treatment for ALL follows a structured plan that typically spans about two years. It is divided into three phases, each with a different purpose.
Induction
The first phase, induction, lasts roughly one month. The goal is to destroy as many leukemia cells as possible and restore normal blood cell production. Success, called complete remission, means leukemia cells are no longer visible in bone marrow samples, and blood counts have returned to normal. Most patients achieve remission during induction.
Consolidation
Even after remission, small numbers of leukemia cells can remain hidden in the body. The consolidation phase, which generally lasts a few months, uses intensive treatment to eliminate those remaining cells and reduce the chance of relapse.
Maintenance
The final phase is maintenance, which uses lower doses of treatment given over a longer period, typically around two years. This extended phase is designed to keep the leukemia from returning. It is less intense than the earlier phases, and many patients are able to return to school or work during this time, though regular monitoring continues.
Stem Cell Transplants
Some patients need a stem cell transplant (sometimes called a bone marrow transplant) as part of their treatment. This is not routine for everyone with ALL. The decision depends on risk factors: the genetic profile of the leukemia, how the disease responds to chemotherapy, and whether residual cancer cells persist after treatment.
Transplant is most often recommended for patients with high-risk genetic features (such as certain chromosomal rearrangements or very low chromosome counts), those who take longer than expected to reach remission, or those who still have measurable disease after induction. Interestingly, for patients with the Philadelphia chromosome who respond quickly and deeply to targeted therapy, studies suggest a transplant may not add a survival benefit, which marks a shift from earlier treatment approaches.
CAR-T Cell Therapy
For patients whose leukemia comes back after standard treatment or doesn’t respond to it, a newer approach called CAR-T cell therapy has become an important option. In this treatment, a patient’s own immune cells are collected, genetically reprogrammed in a lab to recognize and attack leukemia cells, and then infused back into the body.
The first CAR-T therapy approved for ALL eliminated leukemia in most children with relapsed disease in clinical trials. It is now a standard, recommended treatment for children and young adults with B-cell ALL that has relapsed after multiple prior treatments. Three CAR-T products are currently approved for ALL: one for children and young adults, and two for adults. Research is also exploring whether CAR-T therapy could be used earlier in the treatment timeline for patients with high-risk disease whose initial chemotherapy has not fully cleared the cancer within six months.
Survival Rates by Age
Age is one of the single biggest factors in ALL outcomes. Children younger than 15 now have a five-year survival rate of approximately 90%, a dramatic improvement from 60% in the 1970s and a testament to decades of clinical trial progress. Adolescents aged 15 to 19 have also seen major gains, with five-year survival rising from 36% in the late 1970s to 78% in recent years.
Adults generally face a tougher prognosis, though outcomes have been improving with the adoption of pediatric-inspired treatment regimens, targeted therapies, and immunotherapies like CAR-T. The gap between childhood and adult survival rates is partly biological: adults are more likely to carry high-risk genetic changes, and their bodies tolerate intensive chemotherapy less well. Still, the overall trajectory across all age groups is moving in a favorable direction.